A paired comparison between glioblastoma "stem cells" and differentiated cells

International Journal of Cancer

Volumn 138, Issue 7, 2016, Pages 1709-1718

  Schneider, Matthias ^a   Ströbele, Stephanie ^a   Nonnenmacher, Lisa ^a   Siegelin, Markus D ^b   Tepper, Melanie ^c   Stroh, Sebastien ^a   Hasslacher, Sebastian ^a   Enzenmüller, Stefanie ^a   Strauss, Gudrun ^a   Baumann, Bernd ^c   Karpel Massler, Georg ^a,b   Westhoff, Mike Andrew ^a   Debatin, Klaus Michael ^a   Halatsch, Marc Eric ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b NewYork Presbyterian Hospital   (United States)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

brain tumour; cancer stem cell; glioblastoma

Indexed keywords

ALKYLATING AGENT; TEMOZOLOMIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN TUMOR; CANCER STEM CELL; CANCER SURVIVAL; CELL DEATH; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL POPULATION; COHORT ANALYSIS; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; LONG TERM SURVIVAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION EXPOSURE; STEM CELL; THERAPY RESISTANCE; TREATMENT RESPONSE; ANIMAL; COMPARATIVE STUDY; DNA FRAGMENTATION; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL DIFFERENTIATION; DNA FRAGMENTATION; GLIOBLASTOMA; HETEROGRAFTS; HUMANS; MICE; NEOPLASTIC STEM CELLS; TUMOR CELLS, CULTURED;

EID: 84955728551     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29908     Document Type: Article

References (55)

1. Lapidot T, Sirard C, Vormoor J, et al., A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-8.
2. Bonnet D, Dick JE., Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730 -7.
3. Magee JA, Piskounova E, Morrison SJ., Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012; 21: 283-96.
4. Baccelli I, Trumpp A., The evolving concept of cancer and metastasis stem cells. J Cell Biol 2012; 198: 281-93.
5. Visvader JE., Cells of origin in cancer. Nature 2011; 469: 314-22.
6. Gupta PB, Fillmore CM, Jiang G, et al., Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011; 146: 633-44.
7. Gottesman MM., Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53: 615-27.
8. Martin-Padura I, Marighetti P, Agliano A, et al., Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab Invest 2012; 92: 952-66.
9. Grotenhuis BA, Wijnhoven BP, van Lanschot JJ., Cancer stem cells and their potential implications for the treatment of solid tumors. J Surg Oncol 2012; 106: 209-15.
10. Persano L, Rampazzo E, Della Puppa A, et al., The three-layer concentric model of glioblastoma: cancer stem cells, microenvironmental regulation, and therapeutic implications. Sci World J 2011; 11: 1829-41.
11. Nduom EK, Hadjipanayis CG, Van Meir EG., Glioblastoma cancer stem-like cells: implications for pathogenesis and treatment. Cancer J 2012; 18: 100-6.
12. Johnson DR, O'Neill BP., Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 2011; 107: 359-64.
13. Westermark B., Glioblastoma-a moving target. Ups J Med Sci 2012; 117: 251-6.
14. Huse JT, Holland EC., Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 2010; 10: 319-31.
15. Giese A., Glioma invasion-pattern of dissemination by mechanisms of invasion and surgical intervention, pattern of gene expression and its regulatory control by tumorsuppressor p53 and proto-oncogene ETS-1. Acta Neurochir Suppl 2003; 88: 153-62.
16. Westhoff MA, Zhou S, Bachem MG, et al., Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells. Oncogene 2008; 27: 5169-81.
17. Karpel-Massler G, Westhoff MA, Kast RE, et al., Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. Anticancer Agents Med Chem 2014; 14: 313-8.
18. Trauth BC, Klas C, Peters AM, et al., Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-5.
19. Westhoff MA, Zhou S, Nonnenmacher L, et al., Inhibition of NF-kappaB signaling ablates the invasive phenotype of glioblastoma. Mol Cancer Res 2013; 11: 1611-23.
20. Syrovets T, Gschwend JE, Buchele B, et al., Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo. J Biol Chem 2005; 280: 6170-80.
21. Iacopino F, Angelucci C, Piacentini R, et al., Isolation of cancer stem cells from three human glioblastoma cell lines: characterization of two selected clones. PLoS One 2014; 9: e105166.
22. Weiswald LB, Bellet D, Dangles-Marie V., Spherical cancer models in tumor biology. Neoplasia 2015; 17: 1-15.
23. Reynolds BA, Weiss S., Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992; 255: 1707-10.
24. Singh SK, Clarke ID, Terasaki M, et al., Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-8.
25. Kyurkchiev D, Naydenov E, Tumangelova-Yuzeir K, et al., Cells isolated from human glioblastoma multiforme express progesterone-induced blocking factor (PIBF). Cell Mol Neurobiol 2014; 34: 479-89.
26. Beier D, Hau P, Proescholdt M, et al., CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010-5.
27. Gunther HS, Schmidt NO, Phillips HS, et al., Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 2008; 27: 2897-909.
28. Ogden AT, Waziri AE, Lochhead RA, et al., Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery 2008; 62: 505-14; discussion 14-5.
29. Facchino S, Abdouh M, Bernier G., Brain cancer stem cells: current status on glioblastoma multiforme. Cancers (Basel) 2011; 3: 1777-97.
30. Nonnenmacher L, Westhoff MA, Fulda S, et al., RIST: a potent new combination therapy for glioblastoma. Int J Cancer 2015; 136: E173-87.
31. Gilbert CA, Ross AH., Cancer stem cells: cell culture, markers, and targets for new therapies. J Cell Biochem 2009; 108: 1031-8.
32. Lee J, Kotliarova S, Kotliarov Y, et al., Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9: 391-403.
33. De Witt Hamer PC, Van Tilborg AA, Eijk PP, et al., The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 2008; 27: 2091-6.
34. Debatin KM, Krammer PH., Death receptors in chemotherapy and cancer. Oncogene 2004; 23: 2950-66.
35. Kontos CK, Christodoulou MI, Scorilas A., Apoptosis-related BCL2-family members: key players in chemotherapy. Anticancer Agents Med Chem 2014; 14: 353-74.
36. Czabotar PE, Lessene G, Strasser A, et al., Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15: 49-63.
37. Chakravarti A, Zhai G, Suzuki Y, et al., The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 2004; 22: 1926-33.
38. Fulda S, Wick W, Weller M, et al., Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002; 8: 808-15.
39. Ströbele S, Schneider M, Schneele L, et al., A potential role for the inhibition of PI3K signaling in glioblastoma therapy. PLoS One 2015; 10: e0131670.
40. Ellis P, Fagan BM, Magness ST, et al., SOX2, a persistent marker for multipotential neural stem cells derived from embryonic stem cells, the embryo or the adult. Dev Neurosci 2004; 26: 148-65.
41. Stupp R, Hegi ME., Targeting brain-tumor stem cells. Nat Biotechnol 2007; 25: 193-4.
42. Mitchison TJ., The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell 2012; 23: 1-6.
43. Beier D, Schulz JB, Beier CP., Chemoresistance of glioblastoma cancer stem cells-much more complex than expected. Mol Cancer 2011; 10: 128.
44. Westhoff MA, Fulda S., Adhesion-mediated apoptosis resistance in cancer. Drug Resist Updat 2009; 12: 127-36.
45. Dahan P, Martinez Gala J, Delmas C, et al., Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance. Cell Death Dis 2014; 5: e1543.
46. Leder K, Pitter K, Laplant Q, et al., Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. Cell 2014; 156: 603-16.
47. Olmez I, Shen W, McDonald H, et al., Dedifferentiation of patient-derived glioblastoma multiforme cell lines results in a cancer stem cell-like state with mitogen-independent growth. J Cell Mol Med 2015; 19: 1262-72.
48. Beck B, Blanpain C., Unravelling cancer stem cell potential. Nat Rev Cancer 2013; 13: 727-38.
49. Kreso A, Dick JE., Evolution of the cancer stem cell model. Cell Stem Cell 2014; 14: 275-91.
50. Huels DJ, Sansom OJ., Stem vs non-stem cell origin of colorectal cancer. Br J Cancer 2015; 113: 1-5.
51. Plaks V, Kong N, Werb Z., The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 2015; 16: 225-38.
52. Chen S, Lewallen M, Xie T., Adhesion in the stem cell niche: biological roles and regulation. Development 2013; 140: 255-65.
53. Friedmann-Morvinski D, Bushong EA, Ke E, et al., Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 2012; 338: 1080-4.
54. Alderton GK., Tumorigenesis: the origins of glioma. Nat Rev Cancer 2011; 11: 627.
55. Tomasetti C, Vogelstein B., Cancer risk: role of environment-response. Science 2015; 347: 729-31.